Compare SOBR & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | ADTX |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | N/A | 2020 |
| Metric | SOBR | ADTX |
|---|---|---|
| Price | $1.41 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 70.8K | ★ 3.9M |
| Earning Date | 11-12-2025 | 11-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $364,164.00 | $5,945.00 |
| Revenue This Year | N/A | $15,768.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 98.07 | N/A |
| 52 Week Low | $1.27 | $1.30 |
| 52 Week High | $22.00 | $8,633.16 |
| Indicator | SOBR | ADTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 37.25 |
| Support Level | $1.40 | $1.30 |
| Resistance Level | $2.17 | $2.20 |
| Average True Range (ATR) | 0.16 | 0.54 |
| MACD | 0.02 | -0.23 |
| Stochastic Oscillator | 1.26 | 1.58 |
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.